BioSpace News Archive

Recycling symbol with arrows made of brown paper on a green textured background. Top view.

Policy

FDA turns to old drugs to address new diseases, persistent medical needs

The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.

May 12, 2026

·

2 min read

·

Tristan Manalac

Indoor boxing ring corner with flooding spotlight .

Cardiovascular disease

BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival

Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.

May 12, 2026

·

2 min read

·

Tristan Manalac

Business

BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.

May 12, 2026

·

2 min read

·

Tristan Manalac

A boat is driving in a circle and produces a big whirlpool

IPO

Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge

After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.

May 12, 2026

·

5 min read

·

Gabrielle Masson

FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie

FDA

FDA’s Makary to resign after Secretary Kennedy signs off

FDA Commissioner Marty Makary intends to resign on Tuesday, according to several sources. This report follows a tumultuous 13-month tenure in which Makary oversaw the controversial rejections of several rare disease drugs and “predictable volatility” within the agency.

May 12, 2026

·

4 min read

·

Annalee Armstrong

Press Releases

CardioPharma Reviews Applications to Explore Non-Cardiovascular Benefits of CVD Polypill

May 12, 2026

·

4 min read

Press Releases

Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine